References 1. Gibbs WW. Dissident or Don Quixote? Scientific American 2001; 265: 30-2. 2. Shackney SE, Berg G, Simon SR, Cohen J, Amina S, et al. Origins and clinical implications of aneuploidy in early bladder cancer. Cytometry 1995; 22: 307-16. 3. Shapiro BL. Down syndrome--a disruption of homeostasis. American Journal of Medical Genetics 1983; 14: 241-69. 4. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994; 18: 163-71. 5. Shen JJ, Williams BJ, Zipursky A, Doyle J, Sherman SL, et al. Cytogenetic and molecular studies of Down syndrome individuals with leukemia. Am J Hum Genet 1995; 56: 915-25. 6. Duesberg PH. Oncogenes and cancer. Science 1995; 267: 1407-8. 7. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proceedings of the National Academy of Sciences (U.S.A.) 1998; 95: 13692-7. 8. Duesberg P, Rasnick D, Li R, Winters L, Rausch C, Hehlmann R. How aneuploidy may cause cancer and genetic instability, In: Root-Bernstein R, Den Otter W, editors. What is cancer? Theories on carcinogenesis. Kapandriti, Greece: Anticancer Research, 1999, pp. 4887-906. 9. Duesberg P, Li R, Rasnick D, Rausch C, Willer A, et al. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genetics and Cytogenetics 2000; 119: 83-93. 10. Duesberg P, Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motility and Cytoskeleton 2000; 47: 81-107. 11. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A 2000; 97: 14295-300. 12. Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci U S A 2001; 98: 11283-8. 13. Li R, Yerganian G, Duesberg P, Kraemer A, Willer A, et al. Aneuploidy 100% correlated with chemical transformation of Chinese hamster cells. Proceedings of the National Academy of Sciences (U.S.A.) 1997; 94: 14506-11. 14. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy versus gene mutation hypothesis: recent study claims mutation, but is found to support aneuploidy. Proceedings of the National Academy of Sciences (USA) 2000; 97: 3236-41. 15. Rasnick D, Duesberg PH. How aneuploidy affects metabolic control and causes cancer. Biochemical Journal 1999; 340: 621-30. 16. Rasnick D. Auto-catalyzed progression of aneuploidy explains the Hayflick limit of cultured cells, carcinogen-induced tumours in mice, and the age distribution of human cancer. Biochemical Journal 2000; 348: 497-506. 17. Rasnick D. Aneuploidy theory explains tumor formation, the absence of immune surveillance and the failure of chemotherapy. Cancer Genetics Cytogenetics 2001; Submitted 18. Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000; 12: 82-8. 19. Hansemann D. Ueber asymmetrische Zelltheilung in epithel Krebsen und deren biologische Bedeutung. Virschows Arch. Pathol. Anat. 1890; 119: 299-326. 20. Boveri T. Zur Frage der Entstehung maligner Tumoren. Jena: Fischer, 1914. 21. Cornish-Bowden A. Metabolic control analysis in biotechnology and medicine. Nature Biotechnology 1999; 17: 641-3. 22. Oreskes N. The Rejection of Continental Drift. New York: Oxford University Press, 1999. 23. Whitman RC. Somatic mutation as a factor in the production of cancer; a critical review of v. Hansemann's theory of anaplasia in the light of modern knowledge of genetics. Journal of Cancer Research 1919; 4: 181-202. 24. Wolf U. Theodor Boveri and his book "On the problem of the origin of malignant tumors", In: German J, editor. Chromosomes and Cancer. New York: John Wiley & Sons, 1974, pp. 3-20. 25. Epstein CJ. The consequences of chromosome imbalance: principles, mechanisms, and models. New York: Cambridge University Press, 1986. 26. Kacser H, Burns JA. The control of flux. Symposia of the Society for Experimental Biology 1973; 27: 65-104. 27. Heinrich R, Rapoport TA. Linear theory of enzymatic chains; its application for the analysis of the crossover theorem and of the glycolysis of human erythrocytes. Acta Biologica et Medica Germanica 1973; 31: 479-94. 28. Kacser H, Burns JA. The molecular basis of dominance. Genetics 1981; 97: 639-66. 29. Kacser H, Burns JA. Molecular democracy: who shares the controls? Biochemical Society Transactions 1979; 7: 1149-60. 30. Fell D. Metabolic control analysis: a survey of its theoretical and experimental development. Biochemical Journal 1992; 286: 313-30. 31. Fell D, Thomas S. Physiological control of metabolic flux: the requirement for multisite modulation. Biochemical Journal 1995; 311: 35-9. 32. Fell D. Understanding the control of metabolism. London: Portland Press, 1997. 33. Kacser H. Recent developments beyond Metabolic Control Analysis. Biochemical Society Transactions 1995; 23: 387-91. 34. Heinrich R, Rapoport TA. A linear steady-state treatment of enzymatic chains. General properties, control and effector strength. European Journal of Biochemistry 1974; 42: 89-95. 35. Kinzler KW, Vogelstein B. Cancer-susceptibility genes: gatekeepers and caretakers. Nature 1997; 386: 761,3. 36. Tomlinson I, Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nature Medicine 1999; 5: 11-2. 37. Epstein SS. The Politics of Cancer Revisited. New York: East Ridge Press, 1998. 38. Kinzler K, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70. 39. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, et al. Gene expression profiles in normal and cancer cells. Science 1997; 276: 1268-72. 40. Wortman M. 2001. DNA chips target Cancer. In Technology Review, pp. 1-5 41. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001; 14: 677-85. 42. Wagner TM, Moslinger R, Langbauer G, Ahner R, Fleischmann E, et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 2000; 82: 1249-53. 43. Arnold K. Study Results Help Define HPV's Role as Diagnostic Tool. J Natl Cancer Inst 2001; 93: 259-60. 44. McCormick F. New-age drug meets resistance. Nature 2001; 412: 281-2. 45. Planck M. Scientific Autobiography and Other Papers pp. 33-34. New York: translated by F. Gaynor, 1949. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.